Cas:651744-38-6 diethyl 3-propan-2-yl-1H-pyrrole-2,4-dicarboxylate manufacturer & supplier

Chemical Name:diethyl 3-propan-2-yl-1H-pyrrole-2,4-dicarboxylate

CAS.NO:651744-38-6

Synonyms:diethyl 3-isopropyl-pyrrole-2,4-dicarboxylate;DIETHYL 3-ISOPROPYL-1H-PYRROLE-2,4-DICARBOXYLATE

Molecular Formula:C₁₃H₁₉NO₄

Molecular Weight:253.29400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:397.144ºC at 760 mmHg

Density:1.118 g/cm3

Index of Refraction:

PSA:68.39000

Exact Mass:253.13100

LogP:2.49150

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like diethyl 3-isopropyl-pyrrole-2,4-dicarboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,DIETHYL 3-ISOPROPYL-1H-PYRROLE-2,4-DICARBOXYLATE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DIETHYL 3-ISOPROPYL-1H-PYRROLE-2,4-DICARBOXYLATE Use and application,DIETHYL 3-ISOPROPYL-1H-PYRROLE-2,4-DICARBOXYLATE technical grade,usp/ep/jp grade.

Related News: The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. diethyl 3-propan-2-yl-1H-pyrrole-2,4-dicarboxylate manufacturer Without disclosing or confirming the number of vaccine doses, the FDA said in a news release that it had authorized two batches of the vaccine for use, that several other batches were not suitable for use and that others were being evaluated. diethyl 3-propan-2-yl-1H-pyrrole-2,4-dicarboxylate supplier Without disclosing or confirming the number of vaccine doses, the FDA said in a news release that it had authorized two batches of the vaccine for use, that several other batches were not suitable for use and that others were being evaluated. diethyl 3-propan-2-yl-1H-pyrrole-2,4-dicarboxylate vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). diethyl 3-propan-2-yl-1H-pyrrole-2,4-dicarboxylate factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.